狼疮性肾炎患儿外周血CD4+CD25+调节性T细胞的变化

目的 探讨狼疮性肾炎(LN)患儿外周血CD4+CD25+调节性T细胞(Tregs)的变化及意义.方法 采用流式细胞术检测30例LN患JL(LN组)和30例健康儿童(对照组)外周血CD4+CD25+调节性T细胞百分比,并分析其与24-h尿微量白蛋白(UMA)及狼疮活动指数(SLE-DAI)的关系.结果 LN患儿外周血中CD4+CD25+Tregs明显低于对照组(P<0.01);CD4+CD25+Tregs 与24-h UMA呈显著负相关,与SLE-DAI呈等级负相关.结论 LN患儿外周血CD4+CD25+Tregs百分比异常降低可能参与LN的起病与发展.CD4+CD25+Tregs百分比与24-h UMA呈显著负相关,与SLE-DAI呈等级负相关,提示可以作为监测LN患儿病情及预后的指标.     

肺癌患者外周血CD4+CD25+调节性T细胞的检测及其临床意义

目的 探讨检测肺癌患者手术前后外周血CD4+CD25+调节性T细胞的临床意义.方法 原发性肺癌患者43例(肺癌组),健康体检者20例(健康对照组).应用流式细胞术检测其外周血CD4+CD25+调节性T细胞的水平.结果 肺癌组患者手术前外周血CD4+CD25+调节性T细胞表达高于健康对照组(P<0.01);肺癌组患者术后30 d时外周血CD4+CD25+调节性T细胞水平较术前明显下降(P<0.05).结论 肺癌患者外周血CD4+CD25+调节性T细胞的水平增高;肺癌患者术后外周血CD4+CD25+调节性T细胞的水平下调,提示术后机体抗肿瘤免疫功能有了一定程度恢复.     

CD4+CD25+调节性T细胞在再生障碍性贫血中的表达及意义

目的:探讨再生障碍性贫血(再障)患者治疗前、后外周血T淋巴细胞亚群、CD4+CD25+T细胞的变化及其临床意义.方法:采用流式细胞术检测23例再障患者治疗前、后外周血T淋巴细胞亚群、CD4+CD25+T细胞的比例,并与健康对照组进行比较.结果:(1)再障患者治疗前CD4+,CD4+/CD8+,CD4+CD25+明显低于健康对照组(P＜0.01),CD8+细胞则明显升高(P＜0.05);重型再障组与慢性再障组比较CD4+CD25+降低,但差异不显著(P＞0.05),CD3+,CD4+,CD4+/CD8+,CD4+CD25+无统计学意义.(2)再障患者治疗后与治疗前相比,CD4+,CD4+/CD8+,CD4+CD25+明显升高(P＜0.01).(3)再障患者治疗有效者与无效者比较CD4+,CD4+/CDs+,CD4+CD25+明显升高(P＜0.01).结论:再障患者存在T淋巴细胞亚群的失调及CD4+CD25+T淋巴细胞的异常表达,且检测外周血T淋巴细胞亚群、CD4+CD25+T细胞有助于了解再障患者的免疫状态、疗效评价及预后判断.     

CD4~+CD25~+调节性T细胞在晚期肺癌中的表达及临床意义

目的探讨CD4+CD25+调节性T细胞(Treg细胞)在晚期肺癌中的表达及其临床意义。方法应用流式细胞术分析30例晚期肺癌患者外周血CD4+CD25+Treg细胞表达水平,与10例健康人比较。结果晚期肺癌患者外周血CD4+CD25+Treg细胞数量增加(17.9±6.1)%,表达高于正常人(6.81±0.4)%(P<0.001)。肺癌患者外周血中Treg细胞数量与患者的病理类型无关(P>0.05),但与临床分期和组织学分化程度有关(P<0.01)。结论Treg细胞在肺癌患者中比率明显升高,并与临床进展有关。     

CD4+CD25+调节性T细胞在Graves眼病中的免疫调节作用

CD4+CD25+调节性T细胞(Treg)具有维持自身免疫耐受和调节免疫应答的功能,其功能紊乱或数量下降是导致自身免疫性疾病的重要原因之一.Graves眼病(graves ophthalmopathy,GO)是自身免疫性疾病,目前其确切的病因及发病机制未完全明确.大量研究表明Treg与自身免疫性甲状腺疾病相关,但Treg在GO发病机制中的作用研究不多.本文将对Treg在GO中的免疫调节作用作一综述.     

CD4+CD25+调节性T细胞在多种类型疫苗中作用的研究进展

CD4⁺CD25⁺ 调节性T细胞具有免疫抑制作用。CD4⁺CD25⁺ 调节性T细胞可由多种类型肿瘤、病原体诱导产生。一方面抑制炎症,防止机体组织损伤;另一方面阻碍机体清除肿瘤细胞和病原体,有利于肿瘤和病原体逃避宿主免疫攻击。使用抗体阻断CD4⁺CD25⁺ 调节性T细胞或干扰其抑制功能则利于机体清除肿瘤和病原体。同样,多种类型疫苗可诱导宿主产生CD4⁺CD25⁺ 调节性T细胞,因而抑制了疫苗引起的免疫反应。使用抗体如抗CD25单克隆抗体等封闭CD4⁺CD25⁺ 调节性T细胞或者抑制其分泌的细胞因子如白细胞介素-10(IL-10)、转化生长因子-β(TGF-β),可增强疫苗的免疫保护效果,从而为寻找更有效的疫苗提供新的思路。     

CD4~+CD25~+调节性T细胞与寄生虫感染免疫的关系

CD4+CD25+调节性T细胞是一类具有免疫抑制性的T淋巴细胞亚群,在自身免疫疾病、移植免疫、肿瘤免疫和感染性疾病中起重要作用[1-4]。已有文献报道,寄生虫感染时,宿主的CD4+CD25+调节性T细胞增殖,在调节机体免受过度免疫病理损伤的过程中发挥着一定的作用[5-6],但是这种作用却不利于宿主有效地清除寄生虫。因此为了更好的认识CD4+CD25+调节性T细胞与寄生虫感染免疫之间的关系,本文就相关研究进展进行综述如下。     

猪囊尾蚴病患者CD4~+ CD25~+调节性T细胞水平的变化

目的检测猪囊尾蚴病患者外周血中CD4+CD25+调节性T淋巴细胞及其FOXP3的表达情况,探讨CD4+CD25+调节性T淋巴细胞在猪囊尾蚴感染中的免疫调控作用及意义。方法采用流式细胞仪检测11例猪囊尾蚴病患者外周血中CD4+CD25+T淋巴细胞的含量,同时观察CD4+CD25+T细胞中表达FOXP3群体的百分含量。结果囊尾蚴病患者外周血中CD4+CD25+T淋巴细胞的百分含量为6.11%,较正常人(3.94%)明显升高(P<0.05);患者外周血中CD4+CD25+T细胞表达FOXP3的细胞百分含量为15.67%,与正常对照组(11.09%)有显著性差异(P<0.05)。结论猪囊尾蚴病患者外周血中CD4+CD25+T淋巴细胞的百分含量显著升高,表明CD4+CD25+调节性T细胞可能参与猪囊尾蚴感染的免疫抑制。     

香菇多糖对原发性肝癌TACE前后外周血CD4+CD25+调节性T细胞的影响

目的 观察香菇多糖在原发性肝癌(TACE)前后对外周血CD4+CD25+调节性T细胞的变化,探讨香菇多糖对原发性肝癌患者的免疫调节机制.方法 原发性肝癌46例,随机分为治疗组24例,对照组22例,治疗组在TACE术后第1天给予香菇多糖1 mg,3次/周,两组化疗方案相同,在TACE前及TACE后4周分别抽外周血,应用流式细胞术检测CD4+CD25+调节性T细胞的变化.结果 外周血CD4+CD25+Treg细胞占CD4+T细胞的百分率:治疗组在TACE前为(10.59±4.34)%、TACE后4周(6.72±2.60)%;对照组在TACE术前为(10.21±4.42)%、TACE后4周为(8.56±3.12)%.在TACE前两组间差异无统计学意义(P>0.05);TACE后4周时治疗组较对照组低,两组间差异有统计学意义(P<0.05).结论 香菇多糖可提高恶性肿瘤患者的免疫功能,在TACE后立即给药效果更佳.     

哮喘患者外周血单个核细胞CD4~+CD25~+调节性T细胞及IL-4分泌水平的检测

目的:探讨CD4+CD25+调节性T细胞在哮喘发病机制中的作用,为哮喘的临床治疗提供新的思路和方法。方法:分离哮喘患者和正常人外周血单个核细胞(PBMC),用流式细胞仪分析CD4+CD25+调节性T细胞在外周血单个核细胞中的比例;酶联免疫吸附法(ELASA)检测外周血PBMC培养上清IL-4的分泌状况。结果:哮喘组外周血CD4+CD25+调节性T细胞的百分率为(3.2±1.5)%,健康对照组为(6.5±2.5)%,哮喘组明显低于对照组(P<0.05);哮喘组外周血PBMC培养上清IL-4分泌水平为(57.3±13.5)ng/L,健康对照组为(28.6±7.2)ng/L,哮喘组明显高于对照组(P<0.05)。结论:CD4+CD25+调节性T细胞可能参与了哮喘的发生与发展。     

CD4+CD25+调节性T细胞与儿科疾病

古希腊特尔斐阿波罗神庙上镌刻着一句铭言:Gnothi Seauton(英文为know thyself)即"认识自己"."认识自己"已成为免疫学家广为认可的定律:机体免疫系统首先必须识别自身的抗原,产生无反应性,再针对外来抗原产生免疫应答,即"识别自身,排斥异己".     

CD4+CD25+ regulatory T cells in health and disease

1. Over the past 5 years, tremendous progress has been made in understanding the suppressive mechanisms of T regulatory (Treg) cells. The Treg cells, a subpopulation of T cells, have been shown to play an important role in maintaining peripheral tolerance and the prevention of autoimmunity. 2. Various populations of Treg cells have been described, including thymically derived CD4(+)CD25(+) Treg cells. These naturally occurring Treg cells are present in the periphery and are capable of suppressing proliferation and effector T cell responses both in vitro and in vivo. 3. In addition, a second subset of Treg cells, type 1 T regulatoary (Tr1) and Th3 cells, exert their suppressive capacity via cytokines such as interleukin-10 and transforming growth factor-beta and are contact independent. 4. The present review summarizes the characteristics and molecular basis of CD4(+)CD25(+) Treg cells, as well as their therapeutic potential in modulating inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis.     

The generation and antigen-specificity of CD4+CD25+ regulatory T cells

CD4+CD25+ regulatory T cells are essential components of the immune system. They help to maintain immune tolerance by exerting suppressive effects on cells of the adaptive and innate immune system. In the last few years there has been an abundance of papers addressing the suppressive effects of CD4+CD25+ regulatory T cells and their putative role in various experimental disease models and human diseases. Despite the enormous amounts of data on these cells a number of controversial issues still exists. CD4+CD25+ regulatory T cells were originally described as thymus-derived anergic/suppressive T cells. Recent papers however indicate that these cells might also be generated in the periphery. Due to the thymic development of CD4+CD25+ regulatory T cells it was thought that these cells were specific for self-antigens. Indeed it was shown that CD4+CD25+ regulatory T cells could be positively selected upon high affinity interaction with self-antigens. However, evidence is accumulating that these cells might also interact with non-self antigens. Finally, in the literature there is conflicting evidence regarding the role of soluble factors versus cell-contact in the mechanism of suppression. The aim of this review is to summarize the evidence supporting these opposing viewpoints and to combine them into a general model for the origin, function and antigen-specificity of CD4+CD25+ regulatory T cells.     

Expression and significance of CD4+ CD25+ FOXP3+ regulatory T cells in patients with systemic lupus erythematosus

目的 探讨系统性红斑狼疮(SLE)患者外周血单个核细胞(PBMC)中CD4+T细胞CD25和FOXP3的表达及其临床意义.方法 流式细胞术检测20例SLE患者(9例为狼疮性肾炎)及10例健康对照组PBMC中CD4+T细胞中CD25及Foxp3的表达.结果 SLE患者CD4+CD25highT细胞中FOXP3+T细胞的表达明显低于健康对照组(P＜0.05),与SLE疾病活动指数SLEDAI积分明显负相关(r=-0.514,P＜0.01),与补体CA正相关(r=0.362,P＜0.05),与ESR及CRP负相关(r分别=-0.23、-0.216,P＜0.05),与外周血免疫球蛋白IgG、IgA、IgM及补体C3水平无明显相关性.将SLE患者分为狼疮性肾炎(LN)组及非肾损(SLE-NR)组,两组CD4+ CD25high T细胞及CD4+ CD25lowT细胞中FOXP3+T细胞的表达均明显低于健康对照组(P＜0.05); LN组CD4+T细胞中CD25high及CD25low的表达均较SLE-NR组增高(P＜0.05).结论 SLE患者外周血中CD4+ CD25highT细胞中FOXP3+的表达水平明显降低,且与疾病活动性相关,而LN患者代偿增高的无FOXP3表达的CD+CD25+T细胞可能与其发病机制有关.     

肺癌患者外周血CD4^＋CD25^＋调节性T细胞的检测及意义

目的研究肺癌患者外周血CD4^＋CD25^＋调节性T细胞（Treg）的比例变化,探讨其与肺癌的临床分期、病理类型及组织学分化程度的相关性。方法采用流式细胞术检测78例肺癌患者（肺癌组）和30例健康对照者（健康对照组）外周血CD4^＋CD25^＋Treg占CD4^＋T细胞的比例。结果肺癌组外周血CD4^＋CD25^＋Treg占CD4’T细胞的比例为（21．07±5．26）％,与健康对照组（10．04±2．75）％比较,差异有统计学意义（P〈0．05）;Ⅲ、Ⅳ期肺癌患者外周血CD4^＋CD25^＋Treg比例分别为（22．46±4．35）％、（24．35±6．20）％,显著高于Ⅰ期＋Ⅱ期肺癌患者（12．89±3．19）％及健康对照组（10．04±2．75）％相比,差异有统计学意义（P〈0．05）;鳞癌、腺癌、小细胞肺癌患者外周血CD4^＋CD25^＋Treg比例分别为（20．75±4．85）％、（21．52±5．26）％、（19．20±6．41）％,与健康对照组比较,差异均有统计学意义（P〈0．05）,但不同病理类型的肺癌患者间外周血CD4^＋CD25^＋Treg比较,差异无统计学意义（P〉0．05）;高分化、中分化、低分化肺癌患者外周血CD4^＋CD25^＋Treg比例分别为（20．36±3．12）％、（21．11±4．67）％、（21．30±5．75）％,显著高于对照组（P〈0．05）,但不同分化程度的各肺癌者间比较,差异无统计学意义（P〉0．05）。结论肺癌患者外周血CD4^＋CD25^＋Treg水平明显升高,且与肺癌的进展密切相关,但与病理类型、组织学分化程度无关。     

Resveratrol induces the suppression of tumor-derived CD4+CD25+ regulatory T cells

CD4+CD25+ regulatory T cells (Treg cells) are negative regulator of the immune system and main obstacles to cancer immunotherapy in tumor-bearing hosts. Resveratrol is a natural product found in grapes with both immunomodulatory and anticancer effects, which can be controlled by Treg cells. Therefore, to determine whether resveratrol performs these actions via Treg cells, we investigated changes in Treg cell population and immunomodulatory cytokines in EG7 tumor-bearing C57BL/6 mice. In the present study, CD4+CD25+ cell population among CD4+ cells was inhibited ex vivo by resveratrol treatment in a dose-dependent manner. FoxP3+ expressing cells among CD4+CD25+ population were significantly reduced after resveratrol treatment ex vivo in intracellular FACS analysis. Single intraperitoneal administration of 4 mg/kg resveratrol suppressed the CD4+CD25+ cell population among CD4+ cells and downregulated secretion of TGF-beta, an immunosuppressive cytokine, measured from the spleens of tumor-bearing mice. Furthermore, resveratrol enhanced IFN-gamma expression in CD8+ T cells both ex vivo and in vivo,leading to immune stimulation. Taken together, these results suggest that resveratrol has a suppressive role on CD4+CD25+ cell population and makes peritumoral microenvironment unfavorable to tumor in tumor-bearing mice. Thus, resveratrol can be considered as possible adjuvant material for vaccination-based cancer therapy.     

The Janus face of CD4+CD25+ regulatory T cells in cancer and autoimmunity

Regulatory T cells (Treg) encompass a heterogeneous family of T cells implicated in maintenance of tolerance to self antigens. Treg cells might be qualitatively and/or quantitatively deficient in human autoimmune diseases, including multiple sclerosis, graft versus host disease, systemic lupus erythematosus, type I diabetes, and rheumatoid arthritis. In animal models of autoimmunity, infusion of ex vivo-expanded Treg cells and/or in vivo enhancement of Treg cell suppressor function by pharmacological agents and cytokines attenuate disease manifestations and restore tolerance. However, Treg cells represent a double-edged sword, as Treg cells with specificity for tumour-associated antigens contribute to cancer pathogenesis and progression. In vivo depletion of Treg cells by monoclonal antibodies and/or selected drugs is an encouraging therapeutic strategy which improves tumour eradication in animal models of cancer. In addition, elimination and/or functional inactivation of Treg cells might boost anti-tumour immunity in tumour-bearing hosts receiving anti-cancer vaccination. The present review discusses Treg cell manipulation as a novel therapeutic strategy in cancer and autoimmunity, conditions characterised by a common regulatory basis.